Abstract:OBJECTIVE:To investigate the relationships between expression of tumor suppressor gene p53 protein, p21(WAF1), clinicopathology and prognosis in human non-small-cell lung carcinoma (NSCLC).METHODS:SP immunohistochemistry performed in all cases.RESULTS:One hundred forty-seven resected NSCLC were examined. There were 63 squamous cell carcinomas, 66 adenocarcinomas, 14 adenosquamous carcinomas and 4 large cell carcinomas. Overall 90 (61.2%) of the 147 cases had positive p53 staining. The positive ratios of p53 overexpression of squamous cell carcinomas, adenocarcinomas, adenosquamous carcinomas and large cell carcinomas were 63.5% (40/63), 57.6% (38/66), 71.4% (10/14) and 50% (2/4) respectively. The average positive ratio of p21(WAF1) expression was 40.1% (59/147) in lung carcinoma. The positive ratios of p21(WAF1) expression of squamous cell carcinomas, adenocarcinomas, adenosquamous carcinomas and large cell carcinomas were 41.3% (26/63), 42.4% (28/66), 28.6% (4/14) and 25% (1/4) respectively. Over expression of p53 protein was associated with prognosis of the patients with adenocarcinomas. The positive ratio of p53 expression in over 3 year survival patients was 75% (21/28) and in less than 3 year survival, 44.7% (17/38) (P < 0.025). The positive expression of p21(WAF1) was related to prognosis of NSCLC. The ratio of 3-year survival (64.4%) in p21(WAF1) positive NSCLC was much higher than in p21(WAF1) negative patients (46.6%) (P < 0.05). Prognosis of patients with p53 positive but p21(WAF1) negative expression was poorer than those with p53 negative and p21(WAF1) positive NSCLC (P < 0.01).CONCLUSION:These findings suggest that over expression of p53 in adenocarcinomas could be used as a prognostic factor for patients. p21(WAF1) is of protein has a definite value in judging the prognosis in NSCLC. Combined expression of p53 and p21(WAF1) can be used as the prognostic markers in NSCLC and are of significance in estimating the prognosis of patients.

Expression of Syk in Non-Small Cell Lung Cancer and Its Relationship with Clinicopathological Parameters

Clinical Significance of Elevated Spleen Tyrosine Kinase Expression in Nasopharyngeal Carcinoma.

Expression and clinical significance of ezrin in non--small-cell lung cancer.

Expression of phospho-MAPK in non-small cell cancer and its clinicopathological significance

Systematic analysis of spleen tyrosine kinase expression and its clinical outcomes in various cancers

[Phophorylated Akt Protein Expression in Non-Small Cell Lung Cancer].

Prognostic Significance of Full-length SYK Expression in Human Hepatocellular Carcinoma

[Association Between Hypermethylation of Syk Gene and Clinicopathological Characteristics in Colorectal Cancer Patients].

Expression of P21, P53 and C-Erbb-2 in Tissues of Non-Small Cell Lung Cancer and Its Clinical Significance

[Expression of Survivin and Its Clinical Significance in Non-Small Cell Lung Cancer].

[Expression and Clinical Significance of P53 Protein and P21(waf1) in Non-Small-cell Lung Carcinoma].

Hypermethylation and prognostic implication of Syk gene in human colorectal cancer

Expressions of Survivin and P53 in Human Non-Small Cell Lung Cancer and Their Relationship

Expression of Skp2 and Its Correlation with C-Myc in Non-Small Cell Lung Cancer

[The Expression of P53, Cyclin D1 and PCNA in Non-Small Cell Lung Cancer].

Expression and Significance of VEGF and P53 in Non Small Cell Lung Cancer

Correlation Study on Expression of P53 Between Non-Small Cell Lung Cancer Cell and Peripheral Blood Lymphocyte

Research on the Reactivation of Syk Expression Caused by the Inhibition of DNA Promoter Methylation in the Lung Cancer.

Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells.

Expression of Nuclear Factor-κB and Its Clinical Significance in Nonsmall-Cell Lung Cancer

SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma